Parallax Volatility Advisers’s Coherus Oncology CHRS Stock Holding History
Bought
Maintained
Sold
Other funds holding CHRS
KKRC
ACB
Parallax Volatility Advisers's CHRS Position: Q4 2022 in Review
Parallax Volatility Advisers sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 7,298 shares — an estimated $70K sold.
Parallax Volatility Advisers first reported a position in CHRS in Q2 2017 and held it in 5 quarters. The position peaked at $220K in Q4 2017. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.
- Parallax Volatility Advisers reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
- Parallax Volatility Advisers sold 7,298 Coherus Oncology shares in Q4 2022, an estimated $70K.
- Parallax Volatility Advisers first reported a position in Coherus Oncology in Q2 2017 and held it in 5 quarters.
- Parallax Volatility Advisers's Coherus Oncology position peaked at $220K in Q4 2017.
- 161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.
Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.